Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Effects of Sojihwangamibang on Hyperlipidemia in Rats Induced by High Cholesterol Diet

소지환가미방이 고지혈 병리인자 및 동물 병태 모델에 미치는 영향

  • Yu, Mao-Lun (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Kim, Dong-Hee (Department of Pathology, College of Oriental Medicine, Daejeon University)
  • 우무륜 (대전대학교 한의과대학 병리학교실) ;
  • 김동희 (대전대학교 한의과대학 병리학교실)
  • Published : 2009.12.25
Download PDF
⟨ Previous Next ⟩

Abstract

This experimental study was designed to investigate the inhibitory effects of Sojihwangamibang on hyperlipidemia in rats induced by high cholesterol diet diet. Sprague- Dawley rats were divided into normal group, control group, SJB treated group. Obese rats were induced by high cholesterol diet treatment for 6 weeks including a oral administration of SJB for 4 weeks. In SJB group, serum total cholesterol, LDL cholesterol, triglyceride and glucose were significantly decreased, and HDL cholesterol was significantly increased compared with untreated control group. In SJB group, HMG-CoA and ACAT concentration of hepatic homogenate were significantly decreased compared with untreated control group. These results provide experimental evidence that SJB, applied currently in the clinical practice, appears to be effective for down-regulating risk factors of hyperlipidemia, and thus may be used as an objective information for the development of therapeutic agents.

Keywords

References

  1. 통계청. 2008 한국의 사회지표. 2009년 2월
  2. Chun, S., Min, W., Park, H., Song, J., Kim, J., Min, Y., Kim, J., Lee, S. The risk groups for coronary heart disease in Koreans. Assessment by distribution of serum lipid concentrations. Clin Chem Lab Med 37: 969-974, 1999 https://doi.org/10.1515/CCLM.1999.143
  3. Kim, J.Q., Song, J., Park, Y.B., Lee, H.K., Kim, Y.S., Ryoo, U.H., Heo, G.B. National cholesterol treatment guidelines in Korean population - setting-up the cutpoints for high blood cholesterol. J Korean Med Sci. 12: 17-22, 1997 https://doi.org/10.3346/jkms.1997.12.1.17
  4. National Cholesterol Education Program National Heart, Lung, and Blood Institute National Institutes of Health. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Executive Summary. NIH Publication No. 01-3670, 2001
  5. Grundy, S.M. Approach to lipoprotein management in 2001 national cholesterol guidelines. Am J Cardiol 90 (suppl):11i-21i, 2002
  6. Fedder, D.O., Koro, C.E., L, G.J. New national cholesterol education program III guidelines for primary prevention lipid-lowering drug therapy. Circulation 105: 152-156, 2002 https://doi.org/10.1161/hc0202.101971
  7. Chuang, P., Langone, A.J. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors. Am J Ther. 14(5):438-441, 2007 https://doi.org/10.1097/01.mjt.0000209693.83065.a6
  8. Adameova, A., Kuzelova, M., Faberova, V., Svec, P. The hypolipidemic effect of a new ACAT inhibitor, VULM 1457, in diabetic-hypercholesterolaemic rats. Pharmazie. 60(9):714-715, 2005
  9. Westerterp, M., de Haan, W., Berb$\acute{e}$e, J.F., Havekes, L.M. Rensen PC. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res. 247(6):1203-1211, 2006
  10. Uhita, K., Masayuki, O., Ohno, K., Hashiguchi, M., Echizen, H., Rikihisa, T., Ogata hiroyasu. Drug Use Evaluation of Antidyslipidemic Agents at a Community Hospital in Japan. PSJ 122(7):499-506, 2002
  11. Sato, N., Fujii, K., Yuge, O. In vivo and in vitro sevoflurane-induced lipid peroxidation in guinea-pig liver microsomes. 75(6):366-370, 1994
  12. Yang, C.C., Kao, C.C. Cardiovascular diseases and the risk of venous thromboembolism: a hospital-based case-control sardy. J Chin Med Assoc. 70(3):103-109, 2007 https://doi.org/10.1016/S1726-4901(09)70339-9
  13. Kannel, W.B. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 52(4):9B-12B, 1983 https://doi.org/10.1016/0002-9149(83)90649-5
  14. Shipley, M.J., Pocock, S.J., Marmot, M.G. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study. BMJ. 303(6794):89-92, 1991 https://doi.org/10.1136/bmj.303.6794.89
  15. Miura, S., Saku, K. Therapies for raising high-density lipoprotein cholesterol. Intern Med. 46(7):339-340, 2007 https://doi.org/10.2169/internalmedicine.46.6206
  16. Schoenhagen, P., Tuzcu, E.M., Apperson-Hansen, C., Wang, C., Wolski, K., Lin, S., Sipahi, I., Nicholls, S.J., Magyar, W.A., Loyd, A., Churchill, T., Crowe, T., Nissen, S.E. Determinants of arterial wall remodeling during lipidlowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation. 113(24):2826-2834, 2006 https://doi.org/10.1161/CIRCULATIONAHA.105.585703
  17. 良石主編. 秘方大全(名醫珍藏). 北京科學技術出版社, 2006
  18. Slowing, K., Ganado, P., Sanz, M., Ruiz, E., Tejerina, T. Study of garlic extracts and fractions on cholesterol plasma levels and vascular reactivity in cholesterol-fed rats. J Nutr. 131(3s):994S-999S, 2001 https://doi.org/10.1093/jn/131.3.994S
  19. Siegel-Axel, D., Daub, K., Seizer, P., Lindemann, S., Gawaz, M. Cardiovasc Res. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis. 78(1):8-17, 2008 https://doi.org/10.1093/cvr/cvn015
  20. Igarashi, K., Tsuji, M., Nishimura, M., Horimoto, M. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. J Clin Apher. 19(1):11-16, 2004 https://doi.org/10.1002/jca.20000
  21. Tang, F.T., Qian, Z.Y., Liu, P.Q., Zheng, S.G., He, S.Y., Bao, L.P., Huang, H.Q. Crocetin improves endotheliumdependent relaxation of thoracic aorta in hypercholesterolemic rabbit by increasing eNOS activity. Biochem Pharmacol. 72(5):558-565, 2006 https://doi.org/10.1016/j.bcp.2006.05.018
  22. 横山. 冠動脈疾患과 酸化스트레스. 炎症, pp 131-138, 2003
  23. 小崎丈太郎. 小山千穂:特集　高脂血症治療の曲がり角　Nikkei Medical 6月号、pp 60-69, 1997
  24. Fruchart, J.C., Duriez, P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 42(1):39-64, 2006 https://doi.org/10.1358/dot.2006.42.1.963528
  25. Shrestha, S., Volek, J.S., Udani, J., Wood, R.J., Greene, C.M., Aggarwal, D., Contois, J.H., Kavoussi, B., Fernandez, M.L. A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals. J Nutr. 136(10):2492-2497, 2006 https://doi.org/10.1093/jn/136.10.2492
  26. Frick, M.H., Elo, O., Haapa, K., Heinonen, O.P., Heinsalmi, P., Helo, P., Huttunen, J.K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317(20):1237-1245, 1987 https://doi.org/10.1056/NEJM198711123172001
  27. Tsutsumi, K., Inoue, Y., Murase, T. Effects of NO-1886, a lipoprotein lipase promoting agent, on homozygous and heterozygous Watanabe heritable hyperlipidaemic rabbits. Arzneimittelforschung. 50(2):118-121, 2000
  28. Jukema, J.W., Bruschke, A.V., van Boven, A.J., Reiber, J.H., Bal, E.T., Zwinderman, A.H., Jansen, H., Boerma, G.J., van Rappard, F.M., Lie, K.I., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderat- ely elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).Circulation. 91(10):2528-2540, 1995 https://doi.org/10.1161/01.CIR.91.10.2528
  29. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., Davis, B.R., Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.N Engl J Med. 335(14):1001-1009, 1996 https://doi.org/10.1056/NEJM199610033351401
  30. Paoletti, R., Fahmy, M., Mahla, G., Mizan, J. and Southworth, H. Rosuvastatin is superior to pravastatin and simvastatin in reducing low-density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve low-density lipoprotein cholesterol targets. Am Coll Cardiol Annual Scientific Session, 2001
  31. 정은아, 김윤경, 김남재, 김동현, 이상인. 가미과루해백황금탕의 항고지혈증 효과. 응용약물학회지 9: 104-111, 2001
  32. Kjorholt, C., Akerfeldt, M.C., Biden, T.J., Laybutt, D.R. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes. 54(9):2755-2763, 2005 https://doi.org/10.2337/diabetes.54.9.2755
  33. Halliwell, B. Biochemical mechanism accounting for the toxic action of oxygen on living organisms. the key role of superoxide dismutase. Cell. Biol. Int. Rep. 2: 11, 1978 https://doi.org/10.1016/0309-1651(78)90079-6
  34. Susan, M.D. and Darry, L.F. Normobaric oxygen toxicity of the lung. New. Engl. J. Med. 303: 76, 1980 https://doi.org/10.1056/NEJM198007103030204
  35. Freman, B.A. and Crapo, J.D. Biology of disease : Free radicals and tissue injury. Lab. Invest. 47: 412, 1982
  36. Vaziri, N.D., Liang, K. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int. 61(5):1769-1775, 2002 https://doi.org/10.1046/j.1523-1755.2002.00319.x
  37. Vaziri, N.D., Liang, K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure.Am J Physiol Renal Physiol. 287(5):F1038-1043, 2004 https://doi.org/10.1152/ajprenal.00150.2004
  38. Zoltowska, M., Delvin, E.E., Paradis, K., Seidman, E., Levy, E. Bile duct cells: a novel in vitro model for the study of lipid metabolism and bile acid production. Am J Physiol. 276(2 Pt 1):G407-414, 1999
  39. Liang, K., Kim, C.H., Vaziri, N.D. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.Am J Physiol Renal Physiol. 288(3):F539-544, 2005 https://doi.org/10.1152/ajprenal.00074.2004
  40. Roberts, C.K., Liang, K., Barnard, R.J., Kim, C.H., Vaziri, N.D. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X.Kidney Int. 66(4):1503-1511, 2004 https://doi.org/10.1111/j.1523-1755.2004.00914.x
  41. Bocan, T.M., Krause, B.R., Rosebury, W.S., Lu, X., Dagle, C., Bak Mueller, S., Auerbach, B., Sliskovic, D.R. The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.Atherosclerosis. 157(1):97-105, 2001 https://doi.org/10.1016/S0021-9150(00)00713-9
  42. Lee, M.K., Moon, S.S., Lee, S.E., Bok, S.H., Jeong, T.S., Park, Y.B., Choi, M.S. Naringenin 7-O-cetyl ether as inhibitor of HMG-CoA reductase and modulator of plasma and hepatic lipids in high cholesterol-fed rats.Bioorg Med Chem. 11(3):393-398, 2003 https://doi.org/10.1016/S0968-0896(02)00441-8